Dimensional Fund Advisors LP Reduces Holdings in Gilead Sciences, Inc. $GILD

Dimensional Fund Advisors LP decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,557,768 shares of the biopharmaceutical company’s stock after selling 566,769 shares during the quarter. Dimensional Fund Advisors LP owned about 0.77% of Gilead Sciences worth $1,061,087,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in GILD. Brighton Jones LLC raised its stake in shares of Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares during the last quarter. Bison Wealth LLC acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $215,000. Sivia Capital Partners LLC grew its position in Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 602 shares during the period. GHP Investment Advisors Inc. grew its holdings in shares of Gilead Sciences by 1.0% during the 2nd quarter. GHP Investment Advisors Inc. now owns 12,513 shares of the biopharmaceutical company’s stock worth $1,387,000 after purchasing an additional 124 shares during the period. Finally, TIAA Trust National Association increased its position in shares of Gilead Sciences by 0.4% in the second quarter. TIAA Trust National Association now owns 24,560 shares of the biopharmaceutical company’s stock worth $2,723,000 after acquiring an additional 109 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $147.83 on Wednesday. The firm has a fifty day moving average price of $137.07 and a two-hundred day moving average price of $125.27. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The company has a market cap of $183.52 billion, a PE ratio of 21.84, a price-to-earnings-growth ratio of 1.97 and a beta of 0.37. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the prior year, the business posted $1.90 earnings per share. The company’s quarterly revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be issued a $0.82 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio is currently 46.68%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx for about $7.8 billion in cash, materially expanding its oncology and cell‑therapy footprint and signalling strategic diversification away from sole reliance on the HIV franchise — a potential long‑term revenue and valuation kicker if clinical programs progress. Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance
• Positive Sentiment: Recent quarterly results beat on both EPS and revenue and management gave FY‑2026 EPS guidance (8.45–8.85), supporting the earnings story and dividend coverage. This remains a fundamental positive underpin. MarketBeat GILD Coverage (earnings, guidance)
• Neutral Sentiment: Analyst commentary and momentum stories (e.g., Zacks) are supporting investor interest but are sentiment drivers rather than new fundamentals. Why Gilead Sciences (GILD) is a Top Momentum Stock
• Neutral Sentiment: Gilead presented at the TD Cowen healthcare conference (transcript available) — useful for details on pipeline and strategy but unlikely to immediately move the stock without new data. TD Cowen Presentation Transcript
• Neutral Sentiment: Short‑interest data in recent reports is effectively meaningless (reported as 0 shares/0 days) and is not a driver of today’s move.
• Neutral Sentiment: Gilead Foundation’s $12M award for community HIV prevention is positive PR but immaterial to near‑term financials. Gilead Foundation Awards $12 Million
• Negative Sentiment: CEO Daniel O’Day sold 10,000 shares (reported average ~$144.79) — part of a series of insider sales this quarter. While not large relative to total holdings, insider selling can amplify short‑term selling pressure or raise investor caution. SEC Form 4 — Insider Sale

Insider Activity

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the transaction, the director directly owned 8,920 shares in the company, valued at approximately $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the sale, the insider directly owned 120,288 shares of the company’s stock, valued at $18,577,278.72. This represents a 18.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 309,280 shares of company stock valued at $43,935,470. Insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on GILD. TD Cowen lifted their price target on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Royal Bank Of Canada lifted their price target on Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a report on Wednesday, February 11th. Truist Financial upped their price objective on shares of Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Barclays began coverage on shares of Gilead Sciences in a research report on Friday, February 20th. They issued an “equal weight” rating and a $155.00 price target on the stock. Finally, UBS Group boosted their price objective on Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Twenty-three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $156.72.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.